Posted Jan. 10, 2013 at 12:09 p.m.
GSK
Research Triangle Park, N.C. — GlaxoSmithKline has no plans "at the moment" to spin off its ViiV Healthcare unit that is developing drugs to treat HIV, Patrick Vallance, Glaxo's president of pharmaceuticals research and development, says.
GSK has no plans 'at the moment' to spin off HIV venture
Post a comment
Print this blog postE-mail blog post
Share
GSK
Research Triangle Park, N.C. — GlaxoSmithKline has no plans "at the moment" to spin off its ViiV Healthcare unit that is developing drugs to treat HIV, Patrick Vallance, Glaxo's president of pharmaceuticals research and development, says.
WRAL Tech Wire any time: Twitter, Facebook
Copyright 2013 Bloomberg. All rights reserved.Log in or upgrade to view WRALTechWire Insider content
To access this premium content and other benefits, become a WRAL TechWire Insider. Daily, monthly, and annual memberships available.
Please Log In to add a comment.
Best of TechWire Insider
OUR INSIDERS
WRAL TechWire Editor
The Skinny
Raleigh-based PRA International eyes public offering- Will lightning strike again for veteran entrepreneur Brian Handly at StepLeader?
- Raleigh app developer StepLeader lands $4.4M in first fund raiser
- IBM opens Linux center in China, says it will work with Red Hat
- Red-hot Raleigh startup WedPics hauls in $1.1M in funding
- New Triangle venture capital firm slowly emerging from shadows
- Titans of tech seek to excite UNC, Duke grads about a future beyond themselves
- Triangle politician tries to accelerate crowdfunding; bill passes first hurdle
- ChannelAdvisor seeks $80M, sets share target price for IPO
- IT job openings 28% below 2012 numbers, report shows